Felix Wiedmann1,2,3, Christoph Beyersdorf1,3, Xiao-Bo Zhou2,4, Manuel Kraft1,2,3, Kathrin I Foerster5, Ibrahim El-Battrawy2,4, Siegfried Lang2,4, Martin Borggrefe2,4, Walter E Haefeli5, Norbert Frey1,2,3, Constanze Schmidt1,2,3. 1. Department of Cardiology, Heidelberg University, Heidelberg, Germany. 2. DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg University, Heidelberg, Germany. 3. HCR, Heidelberg Center for Heart Rhythm Disorders, Heidelberg University, Heidelberg, Germany. 4. First Department of Medicine, University Medical Center, Mannheim University, Mannheim, Germany. 5. Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Heidelberg, Germany.
Abstract
BACKGROUND: Upregulation of the two-pore-domain potassium channel TASK-1 (hK2 P 3.1) was recently described in patients suffering from atrial fibrillation (AF) and resulted in shortening of the atrial action potential. In the human heart, TASK-1 channels facilitate repolarization and are specifically expressed in the atria. In the present study, we tested the antiarrhythmic effects of the experimental ion channel inhibitor A293 that is highly affine for TASK-1 in a porcine large animal model of persistent AF. METHODS: Persistent AF was induced in German landrace pigs by right atrial burst stimulation via implanted pacemakers using a biofeedback algorithm over 14 days. Electrophysiological and echocardiographic investigations were performed before and after the pharmacological treatment period. A293 was intravenously administered once per day. After a treatment period of 14 days, atrial cardiomyocytes were isolated for patch clamp measurements of currents and atrial action potentials. Hemodynamic consequences of TASK-1 inhibition were measured upon acute A293 treatment. RESULTS: In animals with persistent AF, the A293 treatment significantly reduced the AF burden (6.5% vs. 95%; P < 0.001). Intracardiac electrophysiological investigations showed that the atrial effective refractory period was prolonged in A293 treated study animals, whereas, the QRS width, QT interval, and ventricular effective refractory periods remained unchanged. A293 treatment reduced the upregulation of the TASK-1 current as well as the shortening of the action potential duration caused by AF. No central nervous side effects were observed. A mild but significant increase in pulmonary artery pressure was observed upon acute TASK-1 inhibition. CONCLUSION: Pharmacological inhibition of atrial TASK-1 currents exerts in vivo antiarrhythmic effects that can be employed for rhythm control in a porcine model of persistent AF. Care has to be taken as TASK-1 inhibition may increase pulmonary artery pressure levels.
BACKGROUND: Upregulation of the two-pore-domain potassium channel TASK-1 (hK2 P 3.1) was recently described in patients suffering from atrial fibrillation (AF) and resulted in shortening of the atrial action potential. In the human heart, TASK-1 channels facilitate repolarization and are specifically expressed in the atria. In the present study, we tested the antiarrhythmic effects of the experimental ion channel inhibitor A293 that is highly affine for TASK-1 in a porcine large animal model of persistent AF. METHODS: Persistent AF was induced in German landrace pigs by right atrial burst stimulation via implanted pacemakers using a biofeedback algorithm over 14 days. Electrophysiological and echocardiographic investigations were performed before and after the pharmacological treatment period. A293 was intravenously administered once per day. After a treatment period of 14 days, atrial cardiomyocytes were isolated for patch clamp measurements of currents and atrial action potentials. Hemodynamic consequences of TASK-1 inhibition were measured upon acute A293 treatment. RESULTS: In animals with persistent AF, the A293 treatment significantly reduced the AF burden (6.5% vs. 95%; P < 0.001). Intracardiac electrophysiological investigations showed that the atrial effective refractory period was prolonged in A293 treated study animals, whereas, the QRS width, QT interval, and ventricular effective refractory periods remained unchanged. A293 treatment reduced the upregulation of the TASK-1 current as well as the shortening of the action potential duration caused by AF. No central nervous side effects were observed. A mild but significant increase in pulmonary artery pressure was observed upon acute TASK-1 inhibition. CONCLUSION: Pharmacological inhibition of atrial TASK-1 currents exerts in vivo antiarrhythmic effects that can be employed for rhythm control in a porcine model of persistent AF. Care has to be taken as TASK-1 inhibition may increase pulmonary artery pressure levels.
Authors: Lijiang Ma; Danilo Roman-Campos; Eric D Austin; Mélanie Eyries; Kevin S Sampson; Florent Soubrier; Marine Germain; David-Alexandre Trégouët; Alain Borczuk; Erika Berman Rosenzweig; Barbara Girerd; David Montani; Marc Humbert; James E Loyd; Robert S Kass; Wendy K Chung Journal: N Engl J Med Date: 2013-07-25 Impact factor: 91.245
Authors: Eric E Lloyd; Randy F Crossland; Sharon C Phillips; Sean P Marrelli; Anilkumar K Reddy; George E Taffet; Craig J Hartley; Robert M Bryan Journal: Hypertension Date: 2011-08-29 Impact factor: 10.190
Authors: Sven H Limberg; Michael F Netter; Caroline Rolfes; Susanne Rinné; Günter Schlichthörl; Marylou Zuzarte; Timon Vassiliou; Rainer Moosdorf; Hinnerk Wulf; Jürgen Daut; Frank B Sachse; Niels Decher Journal: Cell Physiol Biochem Date: 2011-12-14
Authors: Felix Wiedmann; Aytug K Kiper; Mauricio Bedoya; Antonius Ratte; Susanne Rinné; Manuel Kraft; Maximilian Waibel; Priya Anad; Wolfgang Wenzel; Wendy González; Hugo A Katus; Niels Decher; Constanze Schmidt Journal: Cell Physiol Biochem Date: 2019
Authors: Constanze Schmidt; Felix Wiedmann; Xiao-Bo Zhou; Jordi Heijman; Niels Voigt; Antonius Ratte; Siegfried Lang; Stefan M Kallenberger; Chiara Campana; Alexander Weymann; Raffaele De Simone; Gabor Szabo; Arjang Ruhparwar; Klaus Kallenbach; Matthias Karck; Joachim R Ehrlich; István Baczkó; Martin Borggrefe; Ursula Ravens; Dobromir Dobrev; Hugo A Katus; Dierk Thomas Journal: Eur Heart J Date: 2017-06-07 Impact factor: 29.983
Authors: Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins Journal: Eur Heart J Date: 2021-02-01 Impact factor: 29.983
Authors: Manuel Kraft; Kathrin I Foerster; Felix Wiedmann; Max Sauter; Amelie Paasche; Pablo L Blochberger; Baran Yesilgöz; Yannick L'hoste; Norbert Frey; Walter E Haefeli; Jürgen Burhenne; Constanze Schmidt Journal: Pharmaceutics Date: 2022-03-31 Impact factor: 6.321